The Medicare IVIG Access Enhancement Act of 2025 would amend the Social Security Act to broaden in-home intravenous immune globulin (IVIG) coverage under Part B of Medicare. Specifically, it adds chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) to the set of conditions eligible for home IVIG administration, with coverage beginning January 1, 2027.
The bill also adds a new authority to vary payments for home IVIG administration, allowing the Secretary to calibrate reimbursements based on whether the IVIG is used to treat primary immune deficiency disease or CIDP/MMN, subject to notice-and-comment rulemaking. These changes are designed to improve access to at-home care for complex IVIG patients while giving CMS flexibility to align payments with treatment contexts.
At a Glance
What It Does
Expands Medicare home IVIG coverage to CIDP and MMN and authorizes payment variation by treatment type, implemented via CMS rulemaking.
Who It Affects
Medicare beneficiaries with CIDP or MMN, home infusion providers, neurology clinicians, and CMS as the payer and regulator.
Why It Matters
This marks a shift toward in-home management of IVIG for CIDP/MMN, reducing patient travel burdens while introducing a mechanism to align payments with distinct clinical indications.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill amends the Social Security Act to broaden Medicare’s coverage for administering IVIG at home. Under current law, home IVIG coverage is tied to specific immune deficiency conditions; the act adds CIDP and MMN to the covered set, effective beginning January 1, 2027.
In addition to expanding coverage, the bill adds authority for the Secretary to vary payments based on whether IVIG administration is for a primary immune deficiency disease or for CIDP/MMN. This payment variability would be determined through notice-and-comment rulemaking, enabling CMS to calibrate reimbursement to reflect the different clinical contexts and resource requirements of the two groups of indications.
The combination of expanded access and flexible pricing aims to support patients who benefit from in-home care while maintaining oversight over payer costs and care quality. The changes would be implemented by amending Section 1861 and Section 1842 of the Social Security Act.
Implementing rules would need to balance patient access with program integrity and budgetary considerations.
The Five Things You Need to Know
The bill expands Medicare home IVIG coverage to CIDP and MMN, effective January 1, 2027.
Section 1861(s)(2)(Z) is amended to include CIDP and MMN among covered conditions for in-home IVIG treatment.
Section 1861(zz) is amended to reflect CIDP/MMN in the home IVIG coverage framework with a 2027 start date.
Section 1842(o)(8) is amended to authorize payment variation based on the treatment context (PID vs CIDP/MMN).
Payment variations will be set through notice-and-comment rulemaking by the Secretary.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
The act is titled the Medicare IVIG Access Enhancement Act of 2025. This establishes the formal naming convention for the bill and sets the scope for the amendments that follow.
Expansion of in-home IVIG coverage
Subsection 1861(s)(2)(Z) is amended to insert CIDP and MMN after the phrase 'primary immune deficiency diseases,' thereby expanding the set of conditions eligible for in-home IVIG administration. Subsection 1861(zz) is amended to insert the same CIDP/MMN language in the corresponding home IVIG coverage context, with coverage beginning January 1, 2027. These changes institutionalize in-home IVIG delivery for CIDP and MMN within the Medicare program.
Payment variance authority
Section 1842(o)(8) is amended to authorize variation in payments depending on whether IVIG administration is related to treatment of a primary immune deficiency disease or CIDP/MMN, with the exact rates and methods to be determined via a notice-and-comment rulemaking process led by the Secretary. This creates a structured pathway to adjust reimbursement based on clinical context and service modality.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries diagnosed with CIDP who receive in-home IVIG, gaining access and reducing travel burdens.
- Medicare beneficiaries diagnosed with MMN, gaining access to at-home IVIG administration.
- Home infusion therapy providers (pharmacies and home health agencies) that administer IVIG in home settings, benefiting from expanded service demand.
- Neurologists and other clinicians managing CIDP/MMN, who can coordinate care more conveniently for patients receiving home IVIG.
- Caregivers and family members who otherwise would travel to facilities for IVIG administration.
Who Bears the Cost
- The Medicare program and federal taxpayers, due to expanded coverage and potential higher ongoing reimbursements.
- Home infusion providers, who may experience changes in payment structures and administrative requirements under the new variance framework.
- CMS and related contractors responsible for implementing and overseeing the rulemaking process and ensuring program integrity.
Key Issues
The Core Tension
The central tension is balancing broader patient access to in-home IVIG for CIDP/MMN with the policy goal of prudent public expenditure and payment accuracy. On one side, access and quality-of-life benefits argue for generous coverage; on the other, the program must avoid ballooning costs and ensure payments reflect actual resource use and clinical value. The mechanism—rulemaking to set payments—offers flexibility but also introduces transition risk and implementation complexity.
The expansion raises legitimate questions about cost, access, and oversight. While broader in-home IVIG coverage for CIDP and MMN improves patient convenience and may reduce hospital-based care needs, it also increases potential Medicare spend and shifts in provider reimbursement.
The rulemaking process will determine how payment variations are calculated and applied, which introduces some uncertainty during initial implementation. The policy will require careful monitoring to prevent overuse, fraud, or unintended incentives that could draw resources away from other high-need areas.
Data collection and reporting requirements (even if not spelled out in the bill) will likely be essential to calibrate payment rates and assess real-world impact across regions and patient populations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.